Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy SAN CARLOS, Calif. / Mar 31, 2025 / Business Wire / BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd.,... Read More

BASEL, Switzerland--( BUSINESS WIRE )-- BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1 st . This appointment will enhance the Company’s commitment to bring impactful medicines to more patients across Europe. “We are... Read More

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 SAN MATEO, Calif. / Dec 27, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today... Read More

SAN MATEO, Calif. / Dec 23, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15 th year, changing our ticker to ONC reflects... Read More

SAN MATEO, Calif. / Dec 12, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for... Read More

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitor At a median follow-up of 1.5 years, promising data from the 320 mg... Read More

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely to be efficacious Campaign highlights national treatment guidelines supporting targeted therapies rather than chemotherapy for improved CLL outcomes BeiGene and CLL Society launch partnership during the American Society of... Read More

SAN MATEO, Calif. / Dec 02, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key presentations at the American... Read More

New indications based on two Phase 3 studies demonstrating statistically significant overall survival benefit for patients treated with TEVIMBRA in combination with chemotherapy SAN MATEO, Calif. / Nov 27, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved... Read More

SAN MATEO, Calif. / Nov 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi’s Global Healthcare Conference on Thursday, December 5... Read More

Agreement provides for generic entry of innovative BTK inhibitor in 2037 SAN MATEO, Calif. / Nov 19, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to... Read More

New name reflects Company’s bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnerships Company will change its Nasdaq ticker to ONC SAN MATEO, Calif. & BASEL, Switzerland / Nov 14, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne... Read More

Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and second consecutive quarter of positive non-GAAP operating income Strengthened franchise leadership in chronic lymphocytic leukemia (CLL) with foundational therapy BRUKINSA global revenue of $690 million, rapidly progressing pivotal... Read More

SAN MATEO, Calif. and BASEL, Switzerland / Nov 06, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies London Healthcare Conference on November 20, 2024, with a fireside chat at 2:30 p.m. GMT. The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com ,... Read More

Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 Oral presentation highlights continued deep and durable responses and manageable tolerability observed in Phase 1 study of BCL2 inhibitor, sonrotoclax, in combination with BRUKINSA for... Read More

SAN MATEO, Calif. / Oct 28, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don... Read More

Positive opinion for first-line treatment of gastric or gastroesophageal junction cancer based on results of RATIONALE-305 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with platinum- and fluoropyrimidine-based chemotherapy Positive opinion for first-line treatment of esophageal squamous cell carcinoma based on results of RATIONALE-306 study demonstrating statistically... Read More

Studies of BRUKINSA ® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif. / Oct 16, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA ® (zanubrutinib), Bruton tyrosine kinase (BTK) chimeric degradation... Read More

Vote recommends a class-wide PD-L1 expression level cut-off across PD-1 inhibitors in advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction cancers Biologics License Applications for TEVIMBRA in these indications are under review with the FDA SAN MATEO, Calif. / Sep 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food... Read More

SAN MATEO, Calif. / Sep 26, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024. “We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth,” said John V. Oyler, Co-Founder, Chairman... Read More

SAN MATEO, Calif. / Sep 09, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. “We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational... Read More

SAN MATEO, Calif. / Aug 28, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com ,... Read More

Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) SAN MATEO, Calif. / Aug 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast... Read More

Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% from the prior-year period; advanced pivotal programs for BCL2... Read More

$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines HOPEWELL, N.J. / Jul 23, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company,... Read More

SAN MATEO, Calif. / Jul 18, 2024 / Business Wire / BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. “We are thrilled to welcome Aaron... Read More

Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results of prior BRUKINSA studies SAN MATEO, Calif. / Jun 14, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology... Read More

SAN MATEO, Calif. / Jun 04, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com ,... Read More

New network meta-analysis demonstrates favorable progression-free survival for patients treated with BRUKINSA vs other BTKi's Analysis of Kaiser Permanente database shows BRUKINSA effective and generally well tolerated, including in patients switching to BRUKINSA from ibrutinib ALPINE post hoc analysis shows less frequent initiation of new antihypertensives or a new class of antihypertensives in patients treated with... Read More

Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in combinations, including with backbone therapy BRUKINSA Phase 1/2 results for BTK degrader BGB-16673 showcasing encouraging efficacy and tolerability, including in... Read More

Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fifth FDA approval, BRUKINSA now has the broadest label in the BTKi class Rapidly advancing late-stage hematology pipeline; sonrotoclax in... Read More

Newly released report details Company’s achievements and plans for sustainable growth BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve... Read More

Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 24, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today... Read More

Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 23, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European... Read More

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 14, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S.... Read More

Armenia and Nepal are the first of 29 countries to receive BRUKINSA SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 13, 2024 / Business Wire / The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene , a global oncology company, and the BeiGene Foundation, a nonprofit... Read More

BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approval based on positive results from ROSEWOOD trial showing BRUKINSA plus obinutuzumab achieved higher overall response rate versus obinutuzumab alone BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 07, 2024 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE:... Read More

Multiple trials underscore the potential of tislelizumab-containing immuno-oncology combinations in a variety of solid tumor settings Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 06, 2024 / Business Wire / BeiGene,... Read More

Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 29, 2024 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 28, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 th , 2024 at 9:50 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 11... Read More

Application based on results from global Phase 3 RATIONALE-305 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer Prescription Drug User Fee Act target action date set for December 2024 BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 27, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today... Read More

Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods Strengthened leadership in hematology with global BRUKINSA ® (zanubrutinib) sales of $413 million and $1.3 billion for the quarter and full year, increases of 135% and 129% Progressed innovative hematology pipeline with initiation of four... Read More

Recommendation based on results of three Phase 3 clinical trials demonstrating benefit of tislelizumab as a first- and second-line treatment for patients with NSCLC BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European... Read More

BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in Canada Follicular lymphoma (FL) is the 2nd most common type of non-Hodgkin lymphoma (NHL) This is the fifth Canadian therapeutic indication for BRUKINSA TORONTO , Feb. 7, 2024 /CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for the use of... Read More

BRUKINSA is now listed on the RAMQ and ODB formularies. Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings. Approximately 2,000 Canadians are diagnosed every year with CLL, the most common form of leukemia in adults. TORONTO , Jan. 31, 2024 /CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jan 23, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. “Dr. Brandicourt brings a... Read More

U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of BRUKINSA versus IMBRUVICA ® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase (BTK) inhibitor trial to demonstrate superiority versus IMBRUVICA BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Dec 22, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160;... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Dec 21, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , 2024 with a presentation at 1:30 pm PT. A live webcast of this event can be accessed from the investors section of BeiGene’s... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 29, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad... Read More

BRUKINSA ® (zanubrutinib) continues to show progression free survival (PFS) benefit compared with ibrutinib in extended follow-up of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) in the ALPINE trial Results of several studies reinforce the favorable efficacy and safety profile for BRUKINSA, including in patients switching from other Bruton’s tyrosine kinase... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass. / Nov 21, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND)... Read More

BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in the European Union Approval was based on results from the ROSEWOOD trial in which BRUKINSA plus the anti-CD20 monoclonal antibody obinutuzumab achieved higher overall response rate compared to obinutuzumab alone BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 17, 2023 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE:... Read More

Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage Global sales of BRUKINSA totaled $358 million, a 130% increase from the prior-year period, driven by launches in the U.S. and Europe First TEVIMBRA approval in EU for 2L esophageal squamous cell carcinoma (ESCC) accelerates global... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 08, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Jefferies London Healthcare Conference on Wednesday, November 15 th , 2023 with a fireside chat at 2:00 pm GMT. A live webcast of this event can be accessed from the investors section of BeiGene’s... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 20, 2023 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a final draft guidance (FDG) recommending BRUKINSA ® (zanubrutinib) for the treatment of eligible adult patients with: Untreated chronic... Read More

First-line tislelizumab plus chemotherapy demonstrated a median overall survival of 15.0 months versus 12.9 months for placebo plus chemotherapy in the intent-to-treat group of the Phase 3 RATIONALE 305 trial The safety profile for tislelizumab in combination with chemotherapy was manageable and in line with the known safety profile of anti-PD-1 antibodies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 17, 2023 /... Read More

Late-breaking ESMO data show 56.2% of patients with resectable NSCLC who received tislelizumab plus chemotherapy before surgery achieved major pathological response, versus 15.0% of those treated with neoadjuvant chemotherapy alone Analysis also found 40.7% of patients on the tislelizumab-based regimen achieved the key secondary endpoint of pathological complete response, compared to 5.7% of patients who received neoadjuvant... Read More

Two late-breaking abstracts highlight tislelizumab plus chemotherapy combination strategy in solid tumors with high unmet need Additional presentations showcase potential of biology-driven tislelizumab combination approaches with BeiGene pipeline molecules BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 16, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,... Read More

CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy If approved, BRUKINSA will be the first and only BTK inhibitor approved for follicular lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 13, 2023 / Business Wire / BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the... Read More

European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC) U.S. FDA accepts Biologics License Application in first-line advanced ESCC BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Sep 19, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has... Read More

Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio, potentially pairing with more than 20 internal investigational assets as part of a broad, flexible combination strategy Regaining global rights furthers Company’s mission of bringing innovative, affordable medicines to more patients and... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Aug 31, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11 th , 2023 with a fireside chat at 9:20 am ET. A live webcast of this event can be accessed from the investors section of... Read More

Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA ® worldwide Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and a 46% increase from the prior quarter; continued execution... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jul 21, 2023 / Business Wire / BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally... Read More

Submission seeks approval for BRUKINSA in combination with obinutuzumab as a treatment for relapsed or refractory follicular lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jul 12, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application... Read More

BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SUZHOU, China & SHANGHAI / Jul 10, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a next-generation ADC... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass / Jul 07, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Company's leadership team, will provide an update on... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023. BeiGene’s work is original, and we will vigorously defend against all... Read More

Oral presentation for the ROSEWOOD trial of BRUKINSA in relapsed or refractory follicular lymphoma Additional presentations expand existing evidence base for BRUKINSA across B-cell malignancies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will present data on its Bruton’s tyrosine... Read More

New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA ® (zanubrutinib) reinforce potential across various B-cell malignancies Early results for BTK-targeted CDAC (BGB-16673) and BCL-2 inhibitor (BGB-11417) in various B-cell malignancies illustrate promise of pipeline BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 09, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:... Read More

BeiGene’s BTKi is approved in more than 65 markets globally BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 30, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia... Read More

Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings TORONTO , May 30, 2023 /CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine... Read More

Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 25, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data showcasing the range of... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 24, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31st at 12:00 pm ET; and Goldman Sachs 44th Annual Global Healthcare Conference on Monday,... Read More

SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 17, 2023 / Business Wire / The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation , a nonprofit charitable foundation, today announced a collaboration to provide access... Read More

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 06, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA... Read More

Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA ® in the U.S. for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); global BRUKINSA product revenue totaled $211.4 million, more than doubling from first quarter 2022 Continued to build on leading position in China oncology market, supported by... Read More

Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 26, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:... Read More

Newly Released Report Details Company’s Progress and Plans for Growing Responsibly BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 25, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the... Read More

Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 20, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn. / Apr 17, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn. / Apr 17, 2023 / Business Wire / MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or... Read More

PD-1 inhibitor tislelizumab under review by Brazil’s National Health Surveillance Agency to treat non-small cell lung cancer and esophageal cancer Future regional expansion planned in Argentina, Mexico, Chile, Colombia, Uruguay, and other countries BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 13, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced... Read More

Pryor will spearhead BeiGene’s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 30, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor has more than 30 years of... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 21, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S. biologic... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 27, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones. “We had an outstanding fourth quarter and 2022, with revenues from our two cornerstone medicines, BRUKINSA ® and tislelizumab,... Read More

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING / Feb 24, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen’s 43 rd Annual Healthcare Conference on Monday, March 6 th , 2023 with a fireside chat at 11:10 am ET. Live webcasts of these events can be accessed from the investors section of BeiGene’s website at... Read More

First and only BTK inhibitor to be granted provincial formulary approval TORONTO , Feb. 6, 2023 /CNW/ - BeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA ® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), for the treatment of adult patients with... Read More

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 03, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being. The data summarized in the report is based on a BeiGene-sponsored study by Cancer Support Community (CSC), a global nonprofit... Read More

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING / Feb 01, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology Conference 2023 on Wednesday, February 8, 2023 at 9:35 a.m. ET; and The SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at... Read More

Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate superior PFS vs IMBRUVICA ® (ibrutinib) BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,... Read More

MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment... Read More

Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS ® included for the first time XGEVA ® successfully renewed BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new... Read More

Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium,... Read More

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT. A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com . An archived replay will be available for 90 days following the event. About BeiGene BeiGene is... Read More

Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in patients with first-line... Read More

Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )-- BeiGene (NASDAQ: BGNE; HKEX: 06160;... Read More

SAN DIEGO , Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal... Read More